Publications of Michael Craig, MD

Effect of bendamustine in combination with rituximab on QT interval duration in patients with advanced de novo indolent non-Hodgkin or mantle cell lymphoma.
Burke JM, van der Jagt RH, Flinn IW, Craig MD, Chen L, Morganroth J, Munteanu MC, MacDonald DA.
Cancer Chemother Pharmacol. 2015;76(1):211-216.


A Phase I study of midostaurin and azacitidine in relapsed and ederly AML patients.
Cooper BW, Kindwall-Keller TL, Craig M, Creger RJ, Hamadani M, Tse WW, Lazarus HM.
Clin Lymphoma Myeloma Leuk. 2015;15(7):428-432.

PMC4484305.

Superior serum concentrations with posaconazole delayed-release tablets compared to suspension formulation in hematological malignancies.
Cumpston AD, Caddell R, Shillingburg A, Lu X, Wen S, Hamadani M, Craig M, Kanate AS.
Antimicrob Agents Chemother. 2015;59(8):4424-4428.

PMC4505228.

Ileal mucosa-associated lymphoid tissue lymphoma presenting with small bowel obstruction: a case report.
Kinkade Z, Esan OA, Rosado FG, Craig M, Vos JA.
Diagn Pathol. 2015;10:105

PMC4504228.

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.
Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst HA, Recher C, Klimek VM, Cortes J, Roboz GJ, Odenike O, Thomas X, Havelange V, Maertens J, Derigs HG, Heuser M, Damon L, Powell BL, Gaidano G, Carella AM, Wei A, Hogge D, Craig AR, Fox JA, Ward R, Smith JA, Acton G, Mehta C, Stuart RK, Kantarjian HM.
Lancet Oncol. 2015;16(9):1025-1036.


Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.
Veltri L, Cumpston AD, Shillingburg AS, Wen S, Luo J, Leadmon S, Watkins K, Craig M, Hamadani M, Kanate AS.
Cytotherapy. 2015;17(12):1785-1792.

PMC4700501.

Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.
Craig M, Hanna WT, Cabanillas F, Chen CS, Esseltine DL, Neuwirth R, O'Connor OA.
Br.J Haematol. 2014;166(6):920-928.


Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Flinn IW, van der Jagt RH, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM.
Blood. 2014;123(19):2944-2952.

PMC4260975.

Predictors and impact of thirty-day readmission on patient outcomes and health care costs after reduced-toxicity conditioning allogeneic hematopoietic cell transplantation.
Rauenzahn S, Truong Q, Cumpston AD, Goff L, Leadmon S, Evans K, Zhang J, Wen S, Craig M, Hamadani M, Kanate AS.
Biol Blood Marrow Transplant. 2014;20(3):415-420.

PMC4557764.

Limited utility of surveillance imaging for detecting disease relapse in patients with non-hodgkin lymphoma in first complete remission.
Truong Q, Shah N, Knestrick M, Curley B, Hu Y, Craig M, Hamadani M.
Clin Lymphoma Myeloma Leuk. 2014;14(1):50-55.


Impact of the duration of antiviral prophylaxis on rates of varicella-zoster virus reactivation disease in autologous hematopoietic cell transplantation recipients.
Truong Q, Veltri L, Kanate AS, Hu Y, Craig M, Hamadani M, Cumpston AD.
Ann Hematol. 2014;93(4):677-682.


Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies.
Awan FT, Kochuparambil ST, Falconer DE, Cumpston AD, Leadmon S, Watkins K, DeRemer D, Jillella A, Craig M, Hamadani M.
Bone Marrow Transplant. 2013;48(10):1279-1284.


Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
Chaudhary LN, Awan FT, Cumpston AD, Leadmon S, Watkins K, Tse WW, Craig M, Hamadani M.
J Clin Apher. 2013;28(5):359-367.


Extended follow-up of an antibiotic cycling program for the management of febrile neutropenia in a hematologic malignancy and hematopoietic cell transplantation unit.
Cumpston AD, Craig M, Hamadani M, Abraham J, Hobbs GR, Sarwari AR.
Transpl Infect Dis. 2013;15(2):142-149.


Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease.
Hamadani M, Gibson LF, Remick SC, Wen S, Petros WP, Tse WW, Brundage KM, Vos JA, Cumpston AD, Bunner P, Craig M.
J Clin Oncol. 2013;31(35):4416-4423.

PMC3842909.

Salvage bone marrow harvest in patients failing Plerixafor-based stem cell mobilization attempt: feasibility and autologous transplantation outcomes.
Kanate AS, Watkins K, Cumpston AD, Craig M, Hamadani M.
Biol Blood Marrow Transplant. 2013;19(7):1133-1135.


Warm Autoimmune Hemolytic Anemia with a direct antiglobulin test positive for C3 and negative for IgG: a case study and analytical literature review of incidence and severity.
Palla AR, Khimani F, Craig M.
Clin Med Insights Case Rep. 2013;6:57-60.

PMC3623608.

Incidence and pattern of graft-versus-host disease in patients undergoing allogeneic transplantation after nonmyeloablative conditioning with total lymphoid irradiation and antithymocyte globulin.
Veltri L, Regier M, Cumpston AD, Leadmon S, Tse WW, Craig M, Hamadani M.
Bone Marrow Res. 2013;2013:414959

PMC3652129.

Plerixafor salvage is safe and effective in hard-to-mobilize patients undergoing cemotherapy and filgrastim-based peripheral blood progenitor cell mobilization.
Awan FT, Kochuparambil ST, DeRemer D, Cumpston AD, Craig M, Jillella A, Hamadani M.
J Oncol. 2012;2012:931071

PMC3335320.

Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation.
Awan FT, Osman S, Kochuparambil ST, Gibson LF, Remick SC, Abraham J, Craig M, Jillella A, Hamadani M.
Bone Marrow Transplant. 2012;47(1):146-148.


Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory Acute Myelogenous Leukemia: results from the CLASSIC I trial.
Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM.
J Clin Oncol. 2012;30(20):2492-2499.


Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell obilization in patients with multiple myeloma treated with novel induction therapies.
Hamadani M, Kochuparambil ST, Osman S, Cumpston AD, Leadmon S, Bunner P, Watkins K, Morrison D, Speir E, DeRemer D, Kota V, Jillella A, Craig M, Awan FT.
Biol Blood Marrow Transplant. 2012;18(7):1128-1135.


A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma.
Hosein PJ, Craig M, Tallman MS, Boccia RV, Hamilton BL, Lewis JJ, Lossos IS.
Am J Hematol. 2012;87(1):111-114.


Melphalan exposure induces an interleukin-6 deficit in bone marrow stromal cells and osteoblasts.
Rellick SL, Piktel D, Walton C, Hall B, Petros WP, Fortney JE, Gencheva M, Denvir J, Hobbs GR, Craig M, Gibson LF.
Cytokine. 2012;58(2):245-252.

PMC3319530.

Evaluation of an alternative posaconazole prophylaxis regimen in haematological malignancy patients receiving concomitant stress ulcer prophylaxis.
Ross AL, Slain D, Cumpston AD, Bryant AM, Hamadani M, Craig M.
Int J Antimicrob Agents. 2012;40(6):557-561.


Impact of alcohol-impregnated port protectors and needleless neutral pressure connectors on central line-associated bloodstream infections and contamination of blood cultures in an inpatient oncology unit.
Sweet MA, Cumpston AD, Briggs F, Craig M, Hamadani M.
Am J Infect Control. 2012;40(10):931-934.


Azacitidine-associated Sweet's syndrome.
Trickett HB, Cumpston AD, Craig M.
Am J Health Syst Pharm. 2012;69(10):869-871.


A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis.
Bryant AM, Slain D, Cumpston AD, Craig M.
Int J Antimicrob Agents. 2011;37(3):266-269.


The evolving role of statins in hematopoietic stem and progenitor cell transplantation.
Hamadani M, Craig M, Gibson LF, Remick SC.
Am J Blood Res. 2011;1(1):57-64.

PMC3301410.

Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning.
Hamadani M, Craig M, Phillips GS, Abraham J, Tse WW, Cumpston AD, Gibson LF, Remick SC, Bunner P, Leadmon S, Elder P, Hofmeister C, Penza S, Efebera Y, Andritsos L, Garzon R, Benson DM, Blum W, Devine SM.
Hematol Oncol. 2011;29(4):202-210.

PMC3557914.

Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation.
Kanate AS, Craig M, Cumpston AD, Saad A, Hobbs GR, Leadmon S, Bunner P, Watkins K, Bulian D, Gibson LF, Abraham J, Remick SC, Hamadani M.
Hematol Oncol Stem Cell Ther. 2011;4(4):149-156.


Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.
Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, Jaffe ES, Ling A, Turner M, Peer CJ, Figg WD, Steinberg SM, Smith S, Joske D, Lewis I, Hutchins L, Craig M, Fojo AT, Wright JJ, Bates SE.
Blood. 2011;117(22):5827-5834.

PMC3112033.

Onset and complications of varicella zoster reactivation in the autologous hematopoietic cell transplant population.
Rogers JE, Cumpston AD, Newton MD, Craig M.
Transpl Infect Dis. 2011;13(5):480-484.


VE-cadherin and PECAM-1 enhance ALL migration across brain microvascular endothelial cell monolayers.
Akers SM, O'Leary HA, Minnear FL, Craig M, Vos JA, Coad JE, Gibson LF.
Exp Hematol. 2010;38(9):733-743.

PMC2929642.

Control of plasma uric acid in adults at risk for Tumor Lysis Syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter Phase III study.
Cortes J, Moore JO, Maziarz RT, Wetzler M, Craig M, Matous J, Luger S, Dey BR, Schiller GJ, Pham D, Abboud CN, Krishnamurthy M, Brown A, Jr., Laadem A, Seiter K.
J Clin Oncol. 2010;28(27):4207-4213.


How we approach patient evaluation for hematopoietic stem cell transplantation.
Hamadani M, Craig M, Awan FT, Devine SM.
Bone Marrow Transplant. 2010;45(8):1259-1268.


Phase II study of clofarabine monotherapy in previously untreated older adults with Acute Myeloid Leukemia and unfavorable prognostic factors.
Kantarjian HM, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T, Gabrilove J, Craig M, Douer D, Maris M, Petersdorf S, Shami PJ, Yeager AM, Eckert S, Abichandani R, Faderl S.
J Clin Oncol. 2010;28(4):549-555.


VE-cadherin regulates Philadelphia chromosome positive acute lymphoblastic leukemia sensitivity to apoptosis.
O'Leary HA, Akers SM, Piktel D, Walton C, Fortney JE, Martin KH, Craig M, Coad JE, Gibson LF.
Cancer Microenviron. 2010;3(1):67-81.

PMC2990486.

Neurotrophins regulate bone marrow stromal cell IL-6 expression through the MAPK pathway.
Rezaee F, Rellick SL, Piedimonte G, Akers SM, O'Leary HA, Martin KH, Craig M, Gibson LF.
PLoS One. 2010;5(3):e9690

PMC2837737.

Can positron emission tomography be used as a staging tool for small-cell lung cancer?
Vinjamuri M, Craig M, Campbell-Fontaine A, Almubarak M, Gupta NC, Rogers JS.
Clin Lung Cancer. 2008;9(1):30-34.


The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit.
Craig M, Cumpston AD, Hobbs GR, Devetten MP, Sarwari AR, Ericson SG.
Bone Marrow Transplant. 2007;39(8):477-482.